1. Scrip

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

Tirzepatide Showed Superiority To Ozempic In Clinical Trials

 
• By Mandy Jackson

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. 

Top view of diabetes tester set with athlete's equipment; measuring tape, green dumbbell and fruit
Beyond diabetes, Lilly is developing tirzepatide for obesity, NASH and heart failure • Source: Shutterstock

Eli Lilly and Company has pledged revenue growth growing forward from selling greater volumes of its drugs rather than from raising the prices for its products. Winning US Food and Drug Administration approval on 13 May for diabetes drug Mounjaro (tirzepatide) is a major milestone in that strategy.

The FDA approved the glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) agonist to improve blood sugar control in adults with type 2 diabetes as an addition to diet and exercise. The agency noted Mounjaro’s ability to both lower blood sugar and induce weight loss in clinical trials with better efficacy than placebo, insulin and Novo Nordisk A/S’s competing GLP-1 agonist Ozempic (semaglutide)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.